MDCX - Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndro
MDCX - Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome - Click For Release
Story updates
12:17:13 PM UTC
SquawkNews
MDCX Medicus Pharma receives FDA “study may proceed” letter for NDA-enabling registrational skinject® study in patients with gorlin syndrome
MDCX - Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome - Click For Release